NCT04662151已完成1 期
A Phase 1b, Randomized, Blinded, Dose-Determined Study Evaluating the Safety and Tolerability Profile of Intervention With AT-100 (rhSP-D) in Preterm Neonates at High Risk for the Development of Bronchopulmonary Dysplasia (BPD)
适应症
干预措施
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 37
- 试验地点
- 19
- 主要终点
- Incidence of BPD or death
研究概览
简要总结
The purpose of this study is to determine if an investigational drug, AT-100, can reduce the occurrence of Bronchopulmonary Dysplasia (BPD) in babies born premature, as compared to babies born premature who receive an air-sham alone.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Prevention
- 盲法
- Single (Participant)
入排标准
- 年龄范围
- 0 Minutes 至 96 Hours（Child）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Preterm neonates born between Gestional Age (GA):
- •25 0/7 weeks to 28 6/7 weeks in the initial dose escalation cohorts.
- •23 0/7 weeks to 28 6/7 weeks in the latter cohort.
- •Intubated and on mechanical ventilation.
- •Receiving at least 1 dose of standard-of-care-indicated surfactant treatment (Curosurf®) after birth, and able to receive the first dose of AT-100 or air-sham within 96 hours of birth given at any time point after 15 minutes following any of the subject's Curosurf® dose(s).
- •Parent or legal guardian is able to provide informed consent.
排除标准
- •Weight at time of birth < 400 g or > 1,800 g.
- •Major apparent congenital abnormalities impacting cardio and pulmonary function.
- •Active DNR (Do Not Resuscitate) order in place.
- •Known pulmonary air leaks (e.g. pneumothorax and pneumomediastinum) at the time of AT-100 or air-sham administration.
- •History of allergy or sensitivity to any surfactant or any component of the Investigational Product (AT-100).
- •AT-100 or air-sham dosing was set to occur before Data Safety Monitoring Committee recommendation to proceed to the next dose-escalation cohort.
- •Use of minimally invasive surfactant techniques (e.g., LISA, MIST) or INSURE or if, in the opinion of the care team, the infant is very likely too be extubated shortly after receiving Curosurf®.
- •a. Subjects extubated and re-intubated after their Curosurf® dose(s) are eligible, so long as the subject meets Inclusion #
- •Birth mother:
- •Has known active Hepatitis B, C, or E diagnosis.
- •Has a known illness or exposure that, in the judgement of the Investigator, is serious enough to induce an immune deficiency such as Human Immunodeficiency Virus (HIV) and/or is receiving chemotherapy.
- •Has known active Sexually Transmitted Infection (STI).
- •Has known Cytomegalovirus (CMV) active infection.
- •Has known history or evidence of alcohol or drug abuse, wit the exception of marijuana/marijuana-based products/THC, based on a positive maternal or infant drug screen as evidenced by the institution's standard-of-care practice.
- •Concurrent enrollment in an investigational drug, device, or treatment modulation trial that utilizes treatments outside of standard-of-care.
- •Any condition or situation which, in the Investigator's judgement, puts the mother or the neonate at significant risk, could confound the trial results, or may interfere significantly with the mother's or neonate's participation in the trial.
- •Symptomatic and confirmed COVID-19 infection of the mother around the time of birth.
研究组 & 干预措施
Phase 1b open-label air-sham
Sham Comparator
Once daily air-sham via intratracheal administration for up to 2 doses (initial Phase 1b dose-escalation portion) or 7 doses (latter Phase 1b highest tolerated & safety dose level tested portion).
干预措施: Air-sham (Procedure)
Phase 1b open-label AT-100
Experimental
Once daily AT-100 via intratracheal administration for up to 2 doses (initial Phase 1b dose-escalation portion) or 7 doses (latter Phase 1b highest tolerated & safety dose level tested portion).
干预措施: AT-100 (Biological)
结局指标
主要结局
Incidence of BPD or death
时间窗: Week 36 PMA
Number of participants with treatment-related adverse events
时间窗: Adverse events will be followed up to Day 28 of life
Incidence and severity of adverse events between the two treatment groups will be compared
次要结局
未报告次要终点
研究者
研究点 (19)
Loading locations...
相似试验
已完成
2 期
Safety and Efficacy of ART-123 in Subjects With Sepsis and Disseminated Intravascular CoagulationDisseminated Intravascular CoagulationSepsisNCT00487656Artisan Pharma, Inc.750
终止
2 期
A Study of Varespladib Infusion in Subjects With Sickle Cell Disease.Vaso-occlusive CrisisSickle Cell DiseaseNCT01522196Anthera Pharmaceuticals2
已完成
2 期
Pilot Study to Evaluate the Safety and Efficacy of Abatacept in Adults and Children 6 Years and Older With Excessive Loss of Protein in the Urine Due to Either Focal Segmental Glomerulosclerosis (FSGS) or Minimal Change Disease (MCD)Nephrotic SyndromeMinimal Change DiseaseFocal Segmental GlomerulosclerosisNCT02592798Bristol-Myers Squibb36
终止
2 期
AT1001 for the Treatment of COVID-19 Related MIS-CCovid19Multisystem Inflammatory Syndrome in ChildrenNCT05022303Massachusetts General Hospital12
终止
1 期
A Clinical Safety Study on AT-100 in Treating Adults With Severe COVID-19 Infection or Severed Community Acquired PneumoniaCOVID-19NCT04659122Airway Therapeutics, Inc.5